User profiles for "author:R Moots"
Robert MootsAintree University Hospital, Liverpool Verified email at liv.ac.uk Cited by 18269 |
Neutrophil function in inflammation and inflammatory diseases
In inflammatory conditions such as RA, the neutrophil has tended to be dismissed as a short-
lived, terminally differentiated, irrelevant bystander cell. However, this is clearly not the case …
lived, terminally differentiated, irrelevant bystander cell. However, this is clearly not the case …
The multifactorial role of neutrophils in rheumatoid arthritis
Of all cells implicated in the pathology of rheumatoid arthritis (RA), neutrophils possess the
greatest cytotoxic potential, owing to their ability to release degradative enzymes and …
greatest cytotoxic potential, owing to their ability to release degradative enzymes and …
Dopamine receptor expression on human T-and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study
F McKenna, PJ McLaughlin, BJ Lewis… - Journal of …, 2002 - Elsevier
This study documents expression of dopamine (DA) receptors on leukocyte subpopulations
using flow cytometric techniques to identify dopamine receptors with subtype-specific …
using flow cytometric techniques to identify dopamine receptors with subtype-specific …
Birmingham vasculitis activity score (BVAS) Dim system necrotizinig vasculitis
RA Luqmani, PA Bacon, RJ Moots… - … Journal of Medicine, 1994 - academic.oup.com
The continuing morbidity of patients with vasculitis despite the improved prognosis with
aggressive therapy, underlines the need for accurate disease assessment We have devised …
aggressive therapy, underlines the need for accurate disease assessment We have devised …
2018 update of the EULAR recommendations for the management of Behçet's syndrome
Several new treatment modalities with different mechanisms of action have been studied in
patients with Behçet's syndrome (BS). The aim of the current effort was to update the …
patients with Behçet's syndrome (BS). The aim of the current effort was to update the …
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a …
R Fleischmann, E Mysler, S Hall, AJ Kivitz, RJ Moots… - The Lancet, 2017 - thelancet.com
Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid
arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the …
arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the …
The mitochondrial network of human neutrophils: role in chemotaxis, phagocytosis, respiratory burst activation, and commitment to apoptosis
G Fossati, DA Moulding, DG Spiller… - The Journal of …, 2003 - journals.aai.org
It is commonly assumed that human neutrophils possess few, if any, functional mitochondria
and that they do not depend on these organelles for cell function. We have used the …
and that they do not depend on these organelles for cell function. We have used the …
Heavy cigarette smoking is strongly associated with rheumatoid arthritis (RA), particularly in patients without a family history of RA
OBJECTIVES To investigate the potential relation between cumulative exposure to cigarette
smoking in patients with or without rheumatoid arthritis (RA) and a positive family history of …
smoking in patients with or without rheumatoid arthritis (RA) and a positive family history of …
[HTML][HTML] Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven …
…, B Dasgupta, A Cauli, P Reynolds, JD Cañete, R Moots… - The Lancet, 2021 - thelancet.com
Background Although targeted biological treatments have transformed the outlook for
patients with rheumatoid arthritis, 40% of patients show poor clinical response, which is …
patients with rheumatoid arthritis, 40% of patients show poor clinical response, which is …
[HTML][HTML] The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis
TC Barnes, ME Anderson, RJ Moots - International journal of …, 2011 - hindawi.com
Interleukin-6 is currently attracting significant interest as a potential therapeutic target in
systemic sclerosis (SSc). In this paper, the biology of interleukin-6 is reviewed, and the …
systemic sclerosis (SSc). In this paper, the biology of interleukin-6 is reviewed, and the …